

SKYEPHARMA PLC  
Form 6-K  
June 28, 2005

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of June, 2005

SkyePharma PLC

---

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

---

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-  
\_\_\_\_\_

---

# Edgar Filing: SKYEPHARMA PLC - Form 6-K

## SkyePharma PLC

### First European Filing for New Aerosol Inhaler Version of AstraZeneca's Pulmicort®

LONDON, ENGLAND, 28 June, 2005 -- SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) announces today aerosol inhaler (pMDI) formulation of the inhaled corticosteroid Pulmicort® (budesonide) has b European market. Pulmicort® HFA-pMDI will be available in two strengths, 100 ug and 200 ug, asthma in adults and children. The currently available pMDI formulation of Pulmicort® has b chlorofluorocarbons (CFCs) as the propellant. In accordance with the Montreal Protocol, thi depleting device using hydrofluoroalkanes (HFA) as propellant. SkyePharma developed the ne proprietary formulation technology, and SkyePharma also conducted the clinical development p triggers a milestone payment to SkyePharma, which will also earn a royalty on AstraZeneca's sales

Michael Ashton, SkyePharma's Chief Executive, said: "We are delighted that Pulmicort® HFA pMDI development and now been filed. This is another example of the growing family of products b delivery technologies."

#### For further information please contact:

##### SkyePharma PLC

Michael Ashton, Chief Executive Officer

Peter Laing, Director of Corporate Communications

+44 207 491 1777

+44 205 491 5124

Sandra Haughton, US Investor Relations

+1 212 753 5780

##### Buchanan Communications

Tim Anderson / Mark Court

+44 207 466 5000

#### Notes to Editors

##### **About SkyePharma**

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery te and more effective drug formulations. There are now eleven approved products incorporating Skye oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabil www.skyepharma.com.

##### **About Pulmicort®**

Pulmicort® (budesonide) is an inhaled corticosteroid indicated for maintenance treatment of a countries Pulmicort® is also indicated for maintenance treatment of Chronic Obstructive Pulmon first registered and launched in 1981 and is now approved in 89 countries. Pulmicort® is availab dry powder inhaler (Pulmicort® Turbuhaler®), as a nebulising suspension (Pulmicort® Respules inhaler (Pulmicort® pMDI).

Pulmicort® is a trademark of the AstraZeneca group of companies

*Certain statements in this news release are forward-looking statements and are made in reliance U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectatio statements are reasonable, it can give no assurance that these expectations will materialize. B risks and uncertainties, actual results may vary significantly from those expressed or impli based upon a number of factors, which are described in SkyePharma's 20-F and other documents on cause differences between actual results and those implied by the forward-looking statements c without limitation, risks related to the development of new products, risks related to obtainin for existing, new or expanded indications of existing and new products, risks related to SkyePh on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability maintain or expand market share in the face of changes in customer requirements, competition an to regulatory compliance, the risk of product liability claims, risks related to the ownership risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obliga forward-looking statement to reflect events or circumstances after the date of this release.*

END

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SkyePharma PLC**

By: /s/ Douglas Parkhill

Name: Douglas Parkhill

Title: Company Secretary

Date: June 28, 2005